PDS Biotechnology Corp (PDSB) stock
PDSBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.44−0.11 (-7.10%)
Close on Oct 30, 2026Market cap $80.60MP/E –Yield –
Earnings
PDS Biotechnology's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Nov 11, 2026
Q3 FY2026 · estimated, before the open
Revenue, Q2 FY2026
–
EPS, Q2 FY2026
-$0.18
-$0.21 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of PDS Biotechnology's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Nov 11, 2026Expected | – | – | – | – |
| Q2 FY2026ended Jun 30, 2026 | Aug 13, 2026before the open | – | – | -$0.18 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 13, 2026before the open | – | – | -$0.13 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 30, 2026before the open | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 12, 2025before the open | – | – | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 13, 2025before the open | – | – | -$0.21 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 14, 2025before the open | – | – | -$0.21 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 27, 2025before the open | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 14, 2024before the open | – | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 13, 2024before the open | – | – | – | Release |
| Q1 FY2024ended Mar 31, 2024 | May 15, 2024before the open | – | – | -$0.30 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 27, 2024before the open | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 14, 2023before the open | – | – | -$0.35 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 14, 2023after the close | – | – | -$0.37 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 15, 2023before the open | – | – | -$0.32 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 28, 2023before the open | – | – | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 14, 2022before the open | – | – | -$0.26 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 8, 2022before the open | – | – | – | Release |
| Q1 FY2022ended Mar 31, 2022 | May 11, 2022before the open | – | – | -$0.32 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 31, 2022before the open | – | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 10, 2021before the open | – | – | -$0.24 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 12, 2021before the open | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 13, 2021before the open | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 18, 2021before the open | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 12, 2020after the close | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Aug 10, 2020after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
PDS Biotechnology has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When PDS Biotechnology puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases PDS Biotechnology filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- News
- Update
- Update
- Results
- Update
- Results
- News
- News
- Results
- News
- News
- News